Physician profile
Gregory E Krill
NPI 1629065081
$654.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $60.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $155.65 | 2019-2020 | |
| Astellas Pharma US INC | $154.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $151.23 | 2019 | |
| Amgen INC. | $44.79 | 2019 | |
| Sanofi Pasteur INC. | $32.36 | 2019 | |
| Medtronic Vascular, INC. | $28.97 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.09 | 2019 | |
| Allergan, INC. | $14.61 | 2019 | |
| Amarin Pharma, INC. | $14.20 | 2019 | |
| Glaxosmithkline, LLC. | $14.04 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Krill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.